CCHT Interpretation of Common Laboratory Values 2 — Questions and Answers

Question 1: A hemodialysis patient's serum phosphorus is 7.8 mg/dL. Which of the following is the most appropriate dietary recommendation to address this finding?

Increase dietary protein intake to improve nutritional status
Restrict foods high in phosphorus such as dairy, nuts, and cola drinks (Correct answer)
Increase dietary potassium to balance electrolytes
No dietary change is needed; adjust phosphate binders only

Correct answer: Restrict foods high in phosphorus such as dairy, nuts, and cola drinks

A serum phosphorus of 7.8 mg/dL is significantly elevated (normal 3.5–5.0 mg/dL for ESRD is targeted at 3.5–5.5 mg/dL). Dietary phosphorus restriction focusing on dairy products, nuts, seeds, and phosphate-additive-containing foods (especially cola drinks) is a primary management strategy alongside phosphate binders.

Hyperphosphatemia is one of the most prevalent metabolic abnormalities in ESRD. The kidneys are the primary route of phosphorus excretion, and when they fail, phosphorus accumulates. Target serum phosphorus in dialysis patients is 3.5–5.5 mg/dL per KDOQI guidelines, though values above 5.5 mg/dL are associated with vascular calcification, bone disease, and increased mortality. Dietary management of hyperphosphatemia focuses on reducing intake of inorganic phosphorus (from food additives, preserved foods, and cola beverages, which contains phosphoric acid), organic phosphorus from animal protein (dairy, meat, eggs), and plant-based phosphorus from legumes, nuts, and seeds. Importantly, not all phosphorus is equally bioavailable—plant phosphorus (phytate-bound) is less absorbed than animal or additive phosphorus. Phosphate binders (calcium carbonate, sevelamer, lanthanum carbonate, sucroferric oxyhydroxide) are prescribed to bind phosphorus in the gut and prevent absorption. Binders must be taken with meals to be effective. Dialysis itself removes approximately 900–1000 mg of phosphorus per session, but this is often insufficient given dietary intake. The CCHT must reinforce dietary counseling, monitor phosphorus trends in monthly labs, confirm binder adherence at each treatment, and communicate significant elevations (>7.0 mg/dL) to the care team. Chronically elevated phosphorus contributes to secondary hyperparathyroidism, renal osteodystrophy, and cardiovascular calcification—serious long-term complications.

Question 2: What does a Kt/V value of 1.2 indicate about a hemodialysis patient's treatment adequacy?

The patient is receiving inadequate dialysis and the treatment time or blood flow rate should be increased
The patient is receiving the minimum adequate dose of dialysis per current guidelines (Correct answer)
The patient is being over-dialyzed and the treatment time should be reduced
The Kt/V value is unrelated to treatment adequacy in hemodialysis

Correct answer: The patient is receiving the minimum adequate dose of dialysis per current guidelines

Kt/V of 1.2 meets the minimum KDOQI recommended target for thrice-weekly hemodialysis (minimum 1.2, target ≥1.4). It indicates the patient is receiving an adequate dose of dialysis, though higher values provide additional benefit.

Kt/V is a dimensionless measure of dialysis adequacy representing the fractional urea clearance per treatment. K = dialyzer urea clearance in mL/min, t = treatment time in minutes, V = urea volume of distribution (roughly 58% of body weight in liters). A single-pool Kt/V (spKt/V) of at least 1.2 per session for thrice-weekly dialysis is the minimum recommended target from KDOQI guidelines; the target is ≥1.4. Kt/V is calculated from pre- and post-dialysis blood urea nitrogen (BUN) values using the Daugirdas second-generation formula, which accounts for urea generation during dialysis and the ultrafiltration effect. Some facilities use the equilibrated Kt/V (eKt/V) or URR (urea reduction ratio) as alternative measures. Factors that affect Kt/V include: blood flow rate (higher flow = more urea clearance), dialysate flow rate, treatment time, dialyzer size (higher KoA = better clearance), and vascular access function. Patients with recirculation in their AV fistula or graft will have lower effective Kt/V. Monthly Kt/V monitoring is required by CMS for all maintenance hemodialysis patients. Values persistently below 1.2 should trigger an assessment of access function, treatment time adherence, blood and dialysate flow rates, and dialyzer choice. The CCHT plays a key role in maximizing delivered Kt/V by optimizing blood flow, minimizing treatment interruptions, and ensuring accurate pre/post BUN sampling.

Question 3: Which laboratory value is used to assess long-term glycemic control in a dialysis patient with diabetes?

Fasting blood glucose
Hemoglobin A1c (HbA1c) (Correct answer)
Serum insulin level
C-peptide level

Correct answer: Hemoglobin A1c (HbA1c)

Hemoglobin A1c (HbA1c) reflects average blood glucose over approximately 2–3 months and is the standard measure of long-term glycemic control. However, in dialysis patients with anemia and frequent transfusions, HbA1c may be falsely low, so fructosamine or glycated albumin may be used as alternatives.

Hemoglobin A1c is formed when glucose attaches non-enzymatically to hemoglobin A in red blood cells. Because red blood cells live approximately 120 days, HbA1c reflects the average blood glucose over that period. A target HbA1c below 7% is recommended for most diabetics, though targets may be liberalized in elderly or frail patients. In dialysis patients, HbA1c interpretation is complicated by several factors. ESRD patients commonly have shorter red blood cell survival (hemolytic anemia, uremic erythropoiesis), which means HbA1c may be artificially low because there are fewer 'old' red cells accumulating glycation. Erythropoiesis-stimulating agents (ESAs) stimulate production of new, less-glycated red cells, further lowering HbA1c. Iron deficiency anemia, conversely, can falsely elevate HbA1c due to reduced red cell turnover. Glycated albumin and fructosamine are alternative markers that reflect shorter-term glycemic control (2–3 weeks for fructosamine, 2–4 weeks for glycated albumin) and are not affected by red cell lifespan, making them potentially more accurate in dialysis patients. The CCHT should be aware that glucose management in dialysis patients is complicated: the dialysate contains dextrose (typically 100 mg/dL), which can affect glucose levels during treatment. Some patients experience hypoglycemia post-dialysis if they are on insulin or sulfonylureas. Blood glucose monitoring during treatment and appropriate insulin adjustments are important safety considerations.

Question 4: A hemodialysis patient's monthly labs show serum potassium of 6.8 mEq/L. What is the most urgent concern?

Development of metabolic acidosis
Risk of fatal cardiac arrhythmias (Correct answer)
Worsening renal bone disease
Increased risk of muscle cramps during dialysis

Correct answer: Risk of fatal cardiac arrhythmias

Hyperkalemia (potassium >6.5 mEq/L) poses an immediate risk of life-threatening cardiac arrhythmias including ventricular fibrillation and asystole. This is the most urgent clinical concern and requires prompt intervention including dietary restriction, dialysate potassium adjustment, and possibly emergency dialysis.

Potassium is the primary intracellular cation and plays a critical role in maintaining the resting membrane potential of cardiac myocytes. The resting membrane potential is determined largely by the ratio of intracellular to extracellular potassium. When serum (extracellular) potassium rises significantly, this ratio changes, partially depolarizing cardiac cells and making them more excitable and prone to arrhythmia. Hyperkalemia in ESRD is common because the kidneys are the primary route of potassium excretion (90% renal, 10% gastrointestinal in normal physiology; the gut compensates partially in CKD but cannot fully compensate in ESRD). Sources of potassium load include dietary intake (especially fruits, vegetables, potatoes, and dairy), tissue breakdown (catabolism, trauma, gastrointestinal bleeding), acidosis (which shifts potassium out of cells), and medications (ACE inhibitors, ARBs, potassium-sparing diuretics, trimethoprim). ECG changes in hyperkalemia appear progressively: peaked T waves (earliest sign), prolonged PR interval, widened QRS, sine wave pattern, and ultimately ventricular fibrillation or asystole. At K⁺ > 6.5 mEq/L, the risk of fatal arrhythmia is significant and urgent treatment is required. Emergency interventions include IV calcium gluconate (membrane stabilization), insulin + dextrose (shifts K⁺ intracellularly), sodium bicarbonate (for acidosis), kayexalate or patiromer (GI binder), and dialysis (most effective removal). The CCHT must communicate a potassium level of 6.8 mEq/L immediately to the nurse and physician before the treatment session begins.

Question 5: What is the target range for serum intact parathyroid hormone (iPTH) in patients on maintenance hemodialysis?

10–65 pg/mL (normal range for healthy adults)
150–600 pg/mL (2–9 times the upper limit of normal) (Correct answer)
600–1000 pg/mL
1000–1500 pg/mL

Correct answer: 150–600 pg/mL (2–9 times the upper limit of normal)

KDIGO guidelines recommend targeting iPTH levels 2–9 times the upper limit of normal for the assay used, which for most laboratories corresponds to approximately 150–600 pg/mL. This range balances suppression of excessive bone remodeling against the risks of adynamic bone disease from over-suppression.

Secondary hyperparathyroidism is a nearly universal complication of ESRD resulting from the combined effects of hyperphosphatemia (which stimulates PTH secretion and inhibits vitamin D activation), hypocalcemia (direct stimulus for PTH release from the parathyroid glands), and calcitriol deficiency (which normally suppresses PTH gene transcription). In the uremic milieu, skeletal resistance to PTH develops, meaning that higher PTH levels are required to achieve normal bone turnover. For this reason, the target iPTH in dialysis patients is deliberately set higher than normal (normal range approximately 15–65 pg/mL) to prevent adynamic bone disease—a low-turnover bone disorder associated with increased fracture risk, vascular calcification, and poor outcomes. The KDIGO CKD-MBD (Chronic Kidney Disease—Mineral and Bone Disorder) guidelines recommend targeting iPTH 2–9 times the upper limit of normal for the specific assay used, while KDOQI guidelines suggest 150–300 pg/mL. There is ongoing debate in nephrology about the optimal target range. Treatment of secondary hyperparathyroidism includes dietary phosphorus restriction, phosphate binders, vitamin D analogues (calcitriol, paricalcitol, doxercalciferol), calcimimetics (cinacalcet, etelcalcetide), and in refractory cases, parathyroidectomy. The CCHT monitors quarterly iPTH results and ensures timely communication of values outside the target range to the care team.

Question 6: A patient's pre-dialysis serum bicarbonate is 14 mEq/L. What condition does this suggest and what is the appropriate response?

Metabolic alkalosis; reduce dialysate bicarbonate concentration
Metabolic acidosis; consider increasing dialysate bicarbonate concentration and notify the care team (Correct answer)
Respiratory acidosis; prepare for non-invasive ventilation
Normal finding in dialysis patients; no action needed

Correct answer: Metabolic acidosis; consider increasing dialysate bicarbonate concentration and notify the care team

A serum bicarbonate of 14 mEq/L is significantly below the target range of 22–26 mEq/L for dialysis patients, indicating metabolic acidosis. This should be communicated to the care team for consideration of higher dialysate bicarbonate concentration or other interventions.

Metabolic acidosis is common in ESRD because the failing kidneys cannot adequately excrete the daily acid load generated by protein metabolism (approximately 1 mEq/kg/day of hydrogen ions) nor regenerate bicarbonate. The resulting chronic metabolic acidosis has multiple detrimental effects: it accelerates protein catabolism and muscle wasting (contributing to malnutrition), worsens secondary hyperparathyroidism and bone disease, impairs cardiac function, promotes inflammation, and is independently associated with increased mortality. The target pre-dialysis serum bicarbonate in dialysis patients is 22–26 mEq/L per KDOQI guidelines. Values below 22 mEq/L represent metabolic acidosis requiring intervention; values of 14 mEq/L represent severe metabolic acidosis. Dialysis corrects acidosis through the bicarbonate-based dialysate, which provides a bicarbonate gradient for diffusion into the blood. Standard dialysate bicarbonate concentration is 35–38 mEq/L, though higher concentrations may be used for patients with persistent severe acidosis. Some patients receive sodium bicarbonate supplementation between treatments for severe or persistent acidosis. Causes of worsening metabolic acidosis in dialysis patients include: inadequate dialysis delivery, increased dietary acid load (high protein intake), diarrhea (bicarbonate loss), medications (acetazolamide, ammonium chloride), and occult metabolic acidosis from sepsis or ischemia. The CCHT should report a bicarbonate of 14 mEq/L to the nurse and document it, as this may require physician review and dialysate prescription adjustment.

CCHT Interpretation of Common Laboratory Values 2

A hemodialysis patient's serum phosphorus is 7.8 mg/dL.
Which of the following is the most appropriate dietary recommendation to address this finding?